JP2024041873A5 - - Google Patents

Download PDF

Info

Publication number
JP2024041873A5
JP2024041873A5 JP2024001623A JP2024001623A JP2024041873A5 JP 2024041873 A5 JP2024041873 A5 JP 2024041873A5 JP 2024001623 A JP2024001623 A JP 2024001623A JP 2024001623 A JP2024001623 A JP 2024001623A JP 2024041873 A5 JP2024041873 A5 JP 2024041873A5
Authority
JP
Japan
Prior art keywords
cells
cancer
population
specific
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024001623A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024041873A (ja
JP7728373B2 (ja
Filing date
Publication date
Priority claimed from JP2020544357A external-priority patent/JP7054418B2/ja
Application filed filed Critical
Publication of JP2024041873A publication Critical patent/JP2024041873A/ja
Publication of JP2024041873A5 publication Critical patent/JP2024041873A5/ja
Application granted granted Critical
Publication of JP7728373B2 publication Critical patent/JP7728373B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024001623A 2017-11-08 2024-01-10 T細胞を製造する組成物及び方法 Active JP7728373B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201762583229P 2017-11-08 2017-11-08
US62/583,229 2017-11-08
US201762588590P 2017-11-20 2017-11-20
US62/588,590 2017-11-20
US201862618445P 2018-01-17 2018-01-17
US62/618,445 2018-01-17
US201862737625P 2018-09-27 2018-09-27
US62/737,625 2018-09-27
JP2020544357A JP7054418B2 (ja) 2017-11-08 2018-11-08 T細胞を製造する組成物及び方法
PCT/US2018/059896 WO2019094642A1 (en) 2017-11-08 2018-11-08 T cell manufacturing compositions and methods
JP2022060497A JP7420856B2 (ja) 2017-11-08 2022-03-31 T細胞を製造する組成物及び方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022060497A Division JP7420856B2 (ja) 2017-11-08 2022-03-31 T細胞を製造する組成物及び方法

Publications (3)

Publication Number Publication Date
JP2024041873A JP2024041873A (ja) 2024-03-27
JP2024041873A5 true JP2024041873A5 (https=) 2024-04-03
JP7728373B2 JP7728373B2 (ja) 2025-08-22

Family

ID=66438061

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020544357A Active JP7054418B2 (ja) 2017-11-08 2018-11-08 T細胞を製造する組成物及び方法
JP2022060497A Active JP7420856B2 (ja) 2017-11-08 2022-03-31 T細胞を製造する組成物及び方法
JP2024001623A Active JP7728373B2 (ja) 2017-11-08 2024-01-10 T細胞を製造する組成物及び方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2020544357A Active JP7054418B2 (ja) 2017-11-08 2018-11-08 T細胞を製造する組成物及び方法
JP2022060497A Active JP7420856B2 (ja) 2017-11-08 2022-03-31 T細胞を製造する組成物及び方法

Country Status (9)

Country Link
US (3) US11162072B2 (https=)
EP (1) EP3706784A4 (https=)
JP (3) JP7054418B2 (https=)
KR (2) KR20230008254A (https=)
CN (2) CN111867618B (https=)
BR (1) BR112020008927A2 (https=)
CA (1) CA3081840A1 (https=)
SG (1) SG11202004116QA (https=)
WO (1) WO2019094642A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018187515A1 (en) 2017-04-04 2018-10-11 Avidea Technologies, Inc. Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
SG11202004116QA (en) 2017-11-08 2020-06-29 Biontech Us Inc T cell manufacturing compositions and methods
CN112584852A (zh) * 2018-06-19 2021-03-30 百欧恩泰美国公司 新抗原及其用途
MX2020014243A (es) 2018-06-19 2021-05-12 Biontech Us Inc Neoantigenos y usos de los mismos.
JP7668226B2 (ja) 2019-03-30 2025-04-24 ビオンテック ユーエス インコーポレイテッド T細胞組成物を調製するための組成物および方法、ならびにそれらの使用
AR118859A1 (es) * 2019-05-08 2021-11-03 Neon Therapeutics Inc Composiciones y métodos de fabricación de células t
GB201911066D0 (en) 2019-08-02 2019-09-18 Achilles Therapeutics Ltd T cell therapy
CN110514845B (zh) * 2019-08-22 2022-09-27 深圳新合睿恩生物医疗科技有限公司 一种肿瘤新生抗原免疫原性检测方法及检测平台
US20230032934A1 (en) * 2019-11-27 2023-02-02 Myst Therapeutics, Llc Method of producing tumor-reactive t cell composition using modulatory agents
GB201918290D0 (en) 2019-12-12 2020-01-29 Achilles Therapeutics Ltd Method
US20230052157A1 (en) 2019-12-12 2023-02-16 Achilles Therapeutics Uk Limited Method for obtaining nucleic acid for sequencing
CN115461062A (zh) 2020-04-28 2022-12-09 阿基里斯治疗英国有限公司 T细胞疗法
CA3158133A1 (en) 2020-04-28 2021-11-04 Lyell Immunopharma, Inc. Methods for culturing cells
CA3176826A1 (en) * 2020-05-04 2021-11-11 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
MX2023001815A (es) * 2020-08-13 2023-04-11 Biontech Us Inc Metodos y composiciones de fabricacion de celulas t.
CA3189269A1 (en) 2020-08-13 2022-02-17 Vikram JUNEJA Ras neoantigens and uses thereof
WO2022115641A2 (en) * 2020-11-25 2022-06-02 Geneius Biotechnology, Inc. Antigen specific t cells and methods of making and using same
JP2024501482A (ja) 2020-12-14 2024-01-12 ビオンテック ユーエス インコーポレイテッド がん免疫療法のための組織特異的抗原
GB202109886D0 (en) 2021-07-08 2021-08-25 Achilles Therapeutics Uk Ltd Assay
EP4320435A1 (en) 2021-04-09 2024-02-14 Achilles Therapeutics UK Limited Batch release assay for pharmaceutical products relating to t cell therapies
US20250195659A1 (en) * 2021-10-15 2025-06-19 Biontech Us Inc. T cell manufacturing compositions and methods
GB202210006D0 (en) 2022-07-07 2022-08-24 Achilles Therapeutics Uk Ltd Analysis of T cell samples
KR20250161543A (ko) * 2023-03-15 2025-11-17 가부시키가이샤 가이아바이오메디신 세포를 현탁하기 위한 액 및 그 이용
WO2025245488A2 (en) * 2024-05-24 2025-11-27 Biontech Us Inc. Compositions and methods for t cell manufacturing and uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
DE69333433T2 (de) 1992-04-01 2004-12-02 The Rockefeller University Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
WO1994003205A1 (en) 1992-08-07 1994-02-17 Cytel Corporation Hla binding peptides and their uses
BR9406652A (pt) 1993-03-05 1996-09-10 Cytel Corp Composição
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU2003270311A1 (en) 2002-09-06 2004-03-29 Mannkind Corporation Epitope sequences
EP1670501A2 (en) * 2003-09-25 2006-06-21 ZymoGenetics, Inc. Methods of treating autoimmune diseases using il-21
WO2006015497A1 (en) 2004-08-13 2006-02-16 Val-Chum, S.E.C. Methods of use of a dkk1 protein, immunogenic polypeptides thereof, nucleic acid encoding the dkk1 protein or polypeptides, or ligands thereof for detecting tumors; and for eliciting immune response against tumors
WO2006110582A1 (en) * 2005-04-08 2006-10-19 Xcyte Therapies, Inc. Compositions and methods for the treatment of burns and sepsis
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
CA2643337C (en) 2006-03-01 2016-01-12 Janssen Pharmaceutica N.V. Cancer treatment combining lymphodepleting agent with ctls and cytokines
WO2009045308A2 (en) 2007-10-03 2009-04-09 Fred Hutchinson Cancer Research Center Enhanced generation of cytotoxic t-lymphocytes by il-21 mediated foxp3 suppression
EP2569633B1 (en) 2010-05-14 2016-02-10 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
WO2012159643A1 (en) 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
DE13746292T1 (de) 2012-02-10 2014-10-30 Hakushinkouseikai Foundation Proliferationsmittel für monozyten, kulturmedium zur proliferation von monozyten, verfahren zur herstellung von monozyten, verfahren zur herstellung dendritischer zellen und verfahren zur herstellung eines impfstoffs mit dendritischen zellen
US20150104441A1 (en) 2013-10-11 2015-04-16 Oslo Universitetssykehus Hf Identification of disease-driving antigens
KR20230076867A (ko) 2013-12-20 2023-05-31 더 브로드 인스티튜트, 인코퍼레이티드 신생항원 백신과의 병용 요법
CN106062185A (zh) * 2014-04-24 2016-10-26 美天旎生物技术有限公司 用于自动生成遗传修饰的t细胞的方法
CN103923880B (zh) 2014-05-08 2016-03-30 成都百赛泰科生物科技有限公司 一种高效增殖、靶向杀伤肿瘤的ctl制备方法
JP6599450B2 (ja) 2014-10-02 2019-10-30 アメリカ合衆国 がん特異的突然変異に対し抗原特異性を有するt細胞を単離する方法
WO2016180852A1 (en) 2015-05-12 2016-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing antigen-specific t cells from an umbilical cord blood sample
CA2992551A1 (en) 2015-07-21 2017-01-26 Novartis Ag Methods for improving the efficacy and expansion of immune cells
AU2016306408B2 (en) 2015-08-10 2021-02-11 Toray Industries, Inc. Immune inducer
US20190119350A1 (en) 2015-09-09 2019-04-25 Immune Design Corp. Ny-eso-1 specific tcrs and methods of use thereof
US10221249B2 (en) 2015-09-10 2019-03-05 Affigen, Llc Method of making patient specific anti-idiotype antibodies
CA3021634A1 (en) 2016-04-15 2017-10-19 Zymeworks Inc. Multi-specific antigen-binding constructs targeting immunotherapeutics
AU2017254477A1 (en) 2016-04-18 2018-11-01 Jennifer G. ABELIN Improved HLA epitope prediction
US11236145B2 (en) 2017-03-23 2022-02-01 Immatics Biotechnologies Gmbh T cell receptors and immune therapy using the same against PRAME positive cancers
BR112020005552A2 (pt) 2017-09-20 2020-10-27 Neximmune, Inc. composições de células compreendendo células t específicas de antígeno para terapia adotiva
SG11202004116QA (en) 2017-11-08 2020-06-29 Biontech Us Inc T cell manufacturing compositions and methods
EP3844265A2 (en) 2018-08-31 2021-07-07 Novartis AG Methods of making chimeric antigen receptor-expressing cells
KR20240091046A (ko) 2018-12-21 2024-06-21 바이오엔테크 유에스 인크. Hla 클래스 ii-특이적 에피토프 예측 및 cd4+ t 세포 특징화를 위한 방법 및 시스템
AR118859A1 (es) 2019-05-08 2021-11-03 Neon Therapeutics Inc Composiciones y métodos de fabricación de células t
MX2023001815A (es) 2020-08-13 2023-04-11 Biontech Us Inc Metodos y composiciones de fabricacion de celulas t.
US20250195659A1 (en) 2021-10-15 2025-06-19 Biontech Us Inc. T cell manufacturing compositions and methods
CN120641112A (zh) 2022-12-09 2025-09-12 百欧恩泰美国公司 T细胞制备组合物和方法

Similar Documents

Publication Publication Date Title
JP2024041873A5 (https=)
JP2021502414A5 (https=)
Zhu T helper cell differentiation, heterogeneity, and plasticity
Sallusto et al. From vaccines to memory and back
Thoman et al. Cell-mediated immunity in aged mice: an underlying lesion in IL 2 synthesis.
JP5184732B2 (ja) T細胞亜集団に特異的なモノクローナル抗体およびポリクローナル抗体の組成物および使用方法
Förster et al. Analysis of orbital T cells in thyroid-associated ophthalmopathy
JP4714767B2 (ja) ヒト血液由来のcd4+cd25+調節t細胞
Monsurrò et al. Quiescent phenotype of tumor-specific CD8+ T cells following immunization
CN109715788A (zh) 用于免疫疗法的t细胞组合物
Kyte et al. T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells
Nagorsen et al. Cytokine and chemokine expression profiles of maturing dendritic cells using multiprotein platform arrays
JP2018506995A5 (https=)
JP2023539056A5 (https=)
US20230357718A1 (en) Methods and materials for expanding antigen-specific t cells in culture
Tjoa et al. Dendritic cell-based immunotherapy for prostate cancer
Gilliet et al. Intranodal injection of semimature monocyte-derived dendritic cells induces T helper type 1 responses to protein neoantigen
Kimura et al. The regulatory role of heat shock protein 70-reactive CD4+ T cells during rat listeriosis.
CN115702927A (zh) 一种广谱性肿瘤疫苗增效的组合物
JP2021534785A5 (https=)
US20030134341A1 (en) Th1 cell adoptive immunotherapy
Ferlazzo Natural killer and dendritic cell liaison: recent insights and open questions
Rohrer et al. Human breast carcinoma patients develop clonable oncofetal antigen-specific effector and regulatory T lymphocytes
JP2022500034A (ja) 抗原特異的tリンパ球ならびに抗原特異的tリンパ球を作製および使用する方法
CN101126076A (zh) TGF-β诱导的调节T细胞及其形成方法和应用